Back to Newsroom

DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Sites open in Europe and New Zealand Enrollment on schedule in trial of dalcetrapib in genetically distinct patients with acute coronary syndrome (ACS) Recently published data showing genotype-dependent effects on cholesterol efflux supports the rationale for the Phase 3 trial Trial steering committee meeting at 2016 ESC Congress

LONDON, August 23, 2016 – DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. DalCor will also be assembling the dal-GenE study’s steering committee at the European Society Cardiology’s ESC Congress taking place in Rome on Aug. 27-31, 2016. The study was initiated in April 2016 in North America and top-line data are expected in 2020.

 

Click here to read the full release